CALTCalliditas Therapeutics AB

Nasdaq calliditas.se


$ 39.05 $ -0.11 (-0.28 %)    

Tuesday, 16-Jul-2024 14:52:58 EDT
QQQ $ 496.22 $ 0.19 (0.04 %)
DIA $ 409.69 $ 7.30 (1.81 %)
SPY $ 564.93 $ 3.33 (0.59 %)
TLT $ 94.14 $ 1.31 (1.41 %)
GLD $ 228.28 $ 4.46 (1.99 %)
$ 38.61
$ 38.95
$ 0.00 x 0
$ 0.00 x 0
$ 38.85 - $ 39.05
$ 15.25 - $ 41.90
2,197
na
2.3B
$ 0.92
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

The clinical trial is a bridging study requiring a limited number of Japanese patients to participate in a study similar in des...

 citigroup-downgrades-calliditas-therapeutics-to-neutral-announces-39-price-target

Citigroup analyst Yigal Nochomovitz downgrades Calliditas Therapeutics (NASDAQ:CALT) from Buy to Neutral and announces $39 p...

 jefferies-downgrades-calliditas-therapeutics-to-hold-lowers-price-target-to-39

Jefferies analyst Maury Raycroft downgrades Calliditas Therapeutics (NASDAQ:CALT) from Buy to Hold and lowers the price targ...

 stifel-downgrades-calliditas-therapeutics-to-hold-lowers-price-target-to-40

Stifel analyst Annabel Samimy downgrades Calliditas Therapeutics (NASDAQ:CALT) from Buy to Hold and lowers the price target ...

 asahi-kasei-makes-11b-offer-for-swedish-drugmaker-calliditas-therapeutics-enhancing-pharma-growth-strategy

Asahi Kasei's $1.1 billion acquisition of Calliditas Therapeutics offers 208 SEK per share in cash. The deal boosts Asahi K...

 hc-wainwright--co-downgrades-calliditas-therapeutics-to-neutral-announces-39-price-target

HC Wainwright & Co. analyst Arthur He downgrades Calliditas Therapeutics (NASDAQ:CALT) from Buy to Neutral and announces...

 calliditas-therapeutics-board-unanimously-recommends-acceptance-of-asahi-kaseis-sek-1116b-tender-offer

STOCKHOLM, May 28, 2024 /PRNewswire/ -- The Board of Directors of Calliditas Therapeutics AB (publ) unanimously recommends that...

 hc-wainwright--co-maintains-buy-on-calliditas-therapeutics-lowers-price-target-to-45

HC Wainwright & Co. analyst Arthur He maintains Calliditas Therapeutics (NASDAQ:CALT) with a Buy and lowers the price ta...

 calliditas-therapeutics-q1-eps-088-down-from-033-yoy-sales-2843m-up-from-1832m-yoy

Calliditas Therapeutics (NASDAQ:CALT) reported quarterly losses of $(0.88) per share. This is a 163.47 percent decrease over lo...